HC Wainwright Reiterates Buy Rating for Adverum Biotechnologies with $30 Price Target.

HC Wainwright & Co. reaffirmed their "Buy" rating for Adverum Biotechnologies (ADVM) with a price target of $30.00. The analyst maintains a positive outlook for the stock, with an expected valuation of $30.00. Based on one-year price targets, the average target is $21.25, indicating an upside of 931.55% from the current price of $2.06. The consensus recommendation is 1.9, indicating "Outperform" status.

On May 15, 2025, HC Wainwright & Co. reaffirmed their "Buy" rating for Adverum Biotechnologies (ADVM), maintaining a price target of $30.00 [1]. The analyst, Matthew Caufield, expressed confidence in the company's prospects, with no change in the price target from the previous assessment. This reiteration suggests a continued positive outlook for Adverum Biotechnologies.

Analysts have forecasted varying one-year price targets for Adverum Biotechnologies, with an average target of $21.25. This average target implies an upside of 931.55% from the current price of $2.06. The consensus recommendation from eight brokerage firms is 1.9, indicating an "Outperform" status [2].

Adverum Biotechnologies, a clinical-stage biotechnology company, focuses on developing gene therapy product candidates for ocular diseases. Its lead product candidate, ixoberogene soroparvovec (ADVM-022), is currently in phase 2 clinical trials for treating wet age-related macular degeneration and diabetic macular edema.

References:
[1] https://www.defenseworld.net/2025/05/17/adverum-biotechnologies-nasdaqadvm-earns-buy-rating-from-hc-wainwright-2.html
[2] https://www.gurufocus.com/news/2865873/adverum-biotechnologies-advm-rating-reiterated-at-buy-by-hc-wainwright-advm-stock-news